Lombard Odier Asset Management (USA)’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,000	Closed	-$711K	–	267
2017 Q2	$711K	Sell	3,000 -333	-10%	-$75.7K	0.06%	202
2017 Q1	$1.15M	Sell	3,333 -2,335	-41%	-$804K	0.11%	159
2016 Q4	$1.98M	Buy	5,668 +213	+4%	+$78K	0.25%	111
2016 Q3	$2.19M	Buy	5,455 +667	+14%	+$340K	0.2%	138
2016 Q2	$2.85M	Buy	4,788 +132	+3%	+$80.2K	0.34%	83
2016 Q1	$2.34M	Buy	4,656 +1,402	+43%	+$698K	0.32%	100
2015 Q4	$2.15M	Buy	+3,254	New	+$1.84M	0.21%	116

Other funds holding EIGR

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $131M AUM 46.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s EIGR Position: Q3 2017 in Review

Lombard Odier Asset Management (USA) sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2017, closing a stake of 3,000 shares — an estimated $711K sold.

Lombard Odier Asset Management (USA) first reported a position in EIGR in Q4 2015 and held it in 7 quarters. The position peaked at $2.85M in Q2 2016. 33 funds tracked by Wall St. Rank hold EIGR as of Q3 2017.

Lombard Odier Asset Management (USA) reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Lombard Odier Asset Management (USA) sold 3,000 Eiger BioPharmaceuticals, Inc. shares in Q3 2017, an estimated $711K.
Lombard Odier Asset Management (USA) first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2015 and held it in 7 quarters.
Lombard Odier Asset Management (USA)'s Eiger BioPharmaceuticals, Inc. position peaked at $2.85M in Q2 2016.
33 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2017.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q3 2017, filed 14 Nov 2017.